Clostridium difficile infection (CDI) is one of the most important causes of nosocomial diarrhoea and is also becoming important in the community and in populations with low or no risk factors.Especially during outbreaks and during the spread of strains with increased virulence it is important that the laboratory diagnosis is rapid and sensitive to ensure appropriate therapy and quick implementation of hospital hygiene measures.Therefore, the improvement of diagnostic methods is becoming more and more important.
This report contains market size and forecasts of Molecular Diagnosis of Clostridium Difficile in global, including the following market information:
Global Molecular Diagnosis of Clostridium Difficile Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Molecular Diagnosis of Clostridium Difficile Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Molecular Diagnosis of Clostridium Difficile companies in 2021 (%)
The global Molecular Diagnosis of Clostridium Difficile market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Sensitivity Above 90% Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Molecular Diagnosis of Clostridium Difficile include Roche, Thermo Scientific, Cepheid (Danaher), BD, Meridian, TECHLAB, Luminex, CerTest Biotec and Quidel, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Molecular Diagnosis of Clostridium Difficile manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Molecular Diagnosis of Clostridium Difficile Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Molecular Diagnosis of Clostridium Difficile Market Segment Percentages, by Type, 2021 (%)
Sensitivity Above 90%
Sensitivity Below 90%
Global Molecular Diagnosis of Clostridium Difficile Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Molecular Diagnosis of Clostridium Difficile Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Laboratory
Home Care
Others
Global Molecular Diagnosis of Clostridium Difficile Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Molecular Diagnosis of Clostridium Difficile Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Molecular Diagnosis of Clostridium Difficile revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Molecular Diagnosis of Clostridium Difficile revenues share in global market, 2021 (%)
Key companies Molecular Diagnosis of Clostridium Difficile sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Molecular Diagnosis of Clostridium Difficile sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Thermo Scientific
Cepheid (Danaher)
BD
Meridian
TECHLAB
Luminex
CerTest Biotec
Quidel
Zhejiang Orient Gene Biotech
Beijing Promed Medical Technology
Jiangsu Besthree Biotechnology